tbuckley/cabot-search huggingface dataset:
Atelectasis following valve treatment
Authors: Daniela Gompelmann, Felix J.F. Herth, Claus Peter Heussel, Ralf Eberhardt
Journal: European Respiratory Journal (2014)

Objective:   Endoscopic valve implantation presents an effective treatment for patients with advanced emphysema. Particularly patients who develop atelectasis benefit from valve therapy.    Methods:   Retrospective analysis of the incidence of a complete atelectasis following valve treatment in patients treated from 01/2008 to 12/2013 in the Thoraxklinik Heidelberg.    Results  : From 01/2008 to 12/2013, 373 patients were treated by valves (217 x EBV (Pulmonx Inc., USA), 101 x IBV (Olympus Inc., Japan), 55 x EBV/IBV). 234 patients received valves on the left, 136 on the right and 3 patients were treated bilaterally. 115 patients (30.8%) experienced a complete atelectasis. The incidence of atelectasis at a rate of 35.9% (84/234) following a left-sided therapy was higher compared to 22.8% (31/136) following a right-sided treatment. 40.1% of the atelectasis (87/217) occurred following EBV placement, 20.8% (21/101) following IBV placement. 12.7% of patients (7/55) who developed atelectasis received EBV as well as IBV. Regarding at the incidence of atelectasis following valve therapy based on the years, a significant increase can be observed.    Discussion:   The overall incidence of an atelectasis following valve therapy in the last 5 years is 30.8%. However, a significant increase can be observed over the years. This can be explained that since the end of 2010 the fissure integrity is increasingly respected.
Advanced Glycation and Lipoxidation End Products
Authors: TOSHIO MIYATA, KIYOSHI KUROKAWA, CHARLES VAN YPERSELE DE STRIHOU
Journal: Journal of the American Society of Nephrology (2000)

The uremic syndrome is usually attributed to the retention of a variety of compounds as a result of a deficient renal clearance. These retention solutes are taken to induce biochemical disorders characteristic of uremic complications. However, as recently noted by Vanholder and De Smet ([1][1]),
Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis
Authors: Bing Li, Junqing Xu, Chengwen Li, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Yue Zhang, Gang Huang, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Shiqiang Qu, Zhijian Xiao
Journal: American Journal of Hematology (2014)

To study the feature and prognostic contribution of cytogenetic information in Chinese patients with primary myelofibrosis (PMF), we analyzed cytogenetic data from 565 patients with PMF. One hundred and sixty-two subjects (29%) had abnormal karyotypes, including trisomy 8 (45; 28%), deletion of 20q (25; 15%), deletion of 13q (13; 8%), deletion of 11q (12; 7%), and abnormal chromosome 1 (21; 13%); balanced translocations (14; 9%); a complex karyotype (CK; 30; 19%), and a monosomal karyotype (MK; 19; 12%). Using these data, we showed that the Dynamic International Prognostic Scoring System (DIPSS)-plus, which includes cytogenetic information, is a better survival predictor than the DIPSS. We next used our data to construct the following two cytogenetic-based cohorts: (1) favorable karyotype—subjects with a normal karyotype, a CK that is not a MK, +8 only or a balanced translocation only and (2) unfavorable karyotype—all others. The median survival times were not reached and were 52 month (95% CI, 32–72 months; P = 0.01) in patients with favorable and unfavorable karyotypes, respectively. These data provided the detailed cytogenetic information in Chinese patients with PMF and confirmed the impact of cytogenetic abnormalities on survival in Chinese patients. Am. J. Hematol. 89:1043–1046, 2014. © 2014 Wiley Periodicals, Inc.
Effects of Different Fractions of &lt;italic&gt;Corynebacterium parvum&lt;/italic&gt; on the Cytotoxic T-Cell Response to Alloantigens in Mice&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: A Lichtenstein, R Tuttle, J Cantrell, J Zighelboim
Journal: JNCI Journal of the National Cancer Institute (1982)

The effects of several biochemically derived fractions of Corynebacterium parvum and chemically treated intact organisms on the generation of cytotoxic T-lymphocytes (CTL) were assessed in a tumor allograft model with the use of C57BL/6 and DBA/2 mice. The acid-modified, active and inactive fragmented preparations and pyridine extract and residue were all capable of inhibiting primary spleen cell allocytotoxicity. Only the active fragmented, pyridine residue and unfractionated preparations caused splenomegaly and prevented the secondary in vitro generation of CTL. Periodate treatment, acid modification, and pyridine extraction abrogated the ability of C. parvum to activate suppressor macrophages. Although incapable of activating suppressor macrophages, the phenol and pyridine extracts significantly enhanced suppressor T-cell activity. The effect of whole C. parvum organisms on T-cell-mediated cytotoxicity is thus extremely complex and due to the direct activation or inhibition of various cell types that interact with each other.
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin- specific antibody fused to single-chain urokinase
Authors: P Holvoet, Y Laroche, JM Stassen, HR Lijnen, B Van Hoef, F De Cock, A Van Houtven, Y Gansemans, G Matthyssens, D Collen
Journal: Blood (1993)
Expression of RNA of an Endogenous Replication-Defective Retrovirus in Rat Mammary Adenocarcinomas Induced by 7,12-Dimethylbenz[a]anthracene2
Authors: Howard A. Young, Martin L. Wenk, Dawn G. Goodman, Edward M. Scolnick
Journal: JNCI Journal of the National Cancer Institute (1978)

An investigation into the possible relationship between chemical carcinogen Induction of rat mammary tumors and the expression of an endogenous retrovlral genome was Initiated. Mammary tumors were Induced In female SO rats with 7,12-dimethylbenz[a]anthracene (OMBA). Tumors, Identified histologically as mammary adenocarcinomas, were analyzed for RNA of a replication-defective endogenous retrovirus or RNA of a helper-independent endogenous type C virus. Expression of RNA of the replication-defective virus was detected In mammary tumors weighing 0.2–2.0 g. Larger tumors, for which histologic examination revealed proportionally more fibroblastic tissue than epithelial cells, did not contain comparable concentrations of this viral RNA. RNA homologous to a helper-independent rat type C retrovirus was not detected in tumors of any size. A cell line was established from a primary OMBA-induced mammary adenocarcinoma and appeared similar to the small mammary tumors with respect to endogenous type C viral RNA expression. We discuss possible implications of the expression of endogenous replication- defective viruses for use as markers for the effects of chemical carcinogens.
Brief Report: Autocrine Cytokine-Mediated Deficiency of TRAIL-Induced Monocyte Apoptosis in Rheumatoid Arthritis
Authors: Undine Meusch, Maria Klingner, Christoph Mathar, Olga Malysheva, Christoph Baerwald, Manuela Rossol, Ulf Wagner
Journal: Arthritis & Rheumatology (2015)

Dysregulated apoptosis of monocytes is a pathogenic feature of rheumatoid arthritis (RA). The aim of this study was to investigate the role of TRAIL and TRAIL-induced apoptosis in patients with RA.Cell surface expression and serum concentrations of TRAIL were determined in 63 patients with RA, and TRAIL-induced monocyte apoptosis was quantified. Surface expression of TRAILR-1, TRAILR-2, TRAILR-3, TRAILR-4, CXCR1, and CXCR2 was determined, and intracellular signal transduction was investigated. In 8 patients with RA, clinical and laboratory parameters of disease activity were investigated longitudinally, before and after initiation of treatment with tumor necrosis factor (TNF) inhibitors.Serum concentrations of both TRAIL and interleukin-8 (IL-8) were increased in patients with RA, while cell surface expression of the TRAIL receptors TRAILR-1, TRAILR-2, TRAILR-3, and TRAILR-4 was diminished. TRAIL-induced monocyte apoptosis was significantly decreased in RA due to increased TRAIL-induced IL-8 secretion by RA monocytes. The combined effect of TRAIL and IL-8 on monocytes resulted in activation of antiapoptotic pathways, including p42/44 MAPK and p38. Susceptibility to TRAIL-induced apoptosis was restored in RA monocytes after 3 months of TNF inhibition.In RA, circulating monocytes with the potential to produce proinflammatory cytokines appear to have defects in several pathways of apoptosis induction, among which is a deficiency in TRAIL-induced apoptosis. Although this resistance to apoptosis might contribute to perpetuation of the disease, it remains to be determined whether specific induction of apoptosis could be therapeutically beneficial.
The Interpersonal Theory of Suicide: Guidance for Working With Suicidal Clientsby JoinerThomas E.Jr. , Van OrdenKimberly A. , WitteTracy K. , and RuddM. David . Washington, D.C., American Psychological Association, 2009, 246pp., $59.95
Authors: Cheryl A. Chessick
Journal: American Journal of Psychiatry (2010)
Abstract 8221: Cis Regulation of Genes in Human Atria Near SNPs Associated with Atrial Fibrillation and PR Interval
Authors: Mina K Chung, John Barnard, Peter Hanna, Jeffrey Hsu, Michael Tchou, Robert C Wirka, Shamone Gore, David Serre, Jonathan D Smith, David R Van Wagoner
Journal: Circulation (2011)

Genome-wide association studies have identified genetic variants in 3 regions associated with atrial fibrillation (AF) and in 9 regions associated with PR interval (PR), an AF-related endophenotype. The mechanisms linking these top variants to the AF phenotype remain unknown. Our study aimed to elucidate these mechanisms by associating SNP genotypes in the 12 implicated regions with proximal (cis) gene expression in human left atria (LA) and by examining differential expression of cis genes with atrial rhythm status at time of surgery. METHODS: Gene expression (Illumina HT12) and SNP genotypes (Illumina Hap550/610) were measured on LA appendages from 234 cardiac surgery patients. Expression and genotypes were preprocessed using best practices. Probes for the 15 genes closest to the top AF and PR-associated SNPs were adjusted for gender, age, genetic stratification and latent expression factors then regressed on their corresponding cis SNP dosage counts to obtain expression quantitative trait SNP (eSNP) p-values. Similar adjustments were done to obtain differential expression p-values. RESULTS: 7 significant eSNPs were found from 14 AF/PR SNPs: rs10033464 (p=0.033) and rs17570669 (9.9e-3) with PITX2 , rs13376333 with KCNN3 (0.046), rs3807989 with CAV1 (4.9e-9), rs11897119 with MEIS1 (2.2e-5), rs427684 with C5orf41 (4.6e-4), rs3825214 with TBX5 (5.0e-3), with rs7660702 marginal for ARHGAP24 (0.077). rs3807989 and rs11897119 were the strongest among all SNPs within 500 KB of their target gene. 8 out of 13 cis genes showed significant differential expression between the No AF (n=38) and AF Rhythm groups (n=100) or between the AF/In Sinus Rhythm (n=100) and AF Rhythm groups, respectively, with 3 showing both: CAV1 (2.1e-3,7.0e-11), TBX5 (0.015,NS), PITX2 (0.015,NS), BNIP1 (0.023,0.026), ARHGAP24 (0.029,2.4e-7), ZFHX3 (0.053,NS), CAV2 (NS,7.1e-3) and C5orf41 (NS,0.025). CONCLUSIONS: We have provided evidence that many of the SNPs associated with AF and PR also associate with expression levels of nearby genes in human left atria and that these genes are differentially expressed in AF.
Abstract 16803: Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-Like Particle Cholesterol From the MARINE and ANCHOR Studies
Authors: Christie M Ballantyne, Harold Bays, Rene Braeckman, Sephy Philip, William Stirtan, Ralph Doyle, Paresh N Soni, Rebecca A Juliano
Journal: Circulation (2014)

Background: Remnant-like particle cholesterol (RLP-C) represents the cholesterol carried by partially catabolized triglyceride (TG)-rich lipoproteins such as very-low-density lipoproteins (VLDL) in the fasted state and chylomicron remnants in the post-prandial state. Increased RLP-C levels are atherogenic and may increase the risk of atherosclerotic cardiovascular disease. Long-chain polyunsaturated omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid reduce RLP-C levels. Icosapent ethyl (IPE) is a high-purity prescription form of EPA ethyl ester approved to reduce TG levels in patients with severe (&gt;=500 mg/dL) hypertriglyceridemia. Objective: To evaluate the effects of IPE on RLP-C levels in patients from the MARINE and ANCHOR studies. Methods: MARINE (TG &gt;=500 and &lt;=2000 mg/dL; N=229) and ANCHOR (TG &gt;=200 and &lt;500 mg/dL despite statin control of low-density lipoprotein cholesterol; N=702) were both 12-week, phase 3, double-blind studies that randomized patients to IPE 4 g/day, 2 g/day, or placebo. This analysis assessed the median percentage change from baseline to study end in RLP-C levels compared with placebo. Serum RLP-C was measured with an immunoseparation assay (Polymedco). Results: In both the MARINE (n=218 with RLP-C data) and ANCHOR (n=252 with RLP-C data) studies, compared with placebo, IPE 4 g/day (Table) and 2 g/day reduced RLP-C levels. Compared with placebo, the approved IPE dose of 4 g/day also reduced RLP-C to a greater extent in subgroups with higher baseline TG levels, reduced RLP-C in statin-treated patients in the MARINE study, and reduced RLP-C in patients receiving moderate- to high-intensity statins in the ANCHOR study. Conclusions: Compared with placebo, IPE reduced RLP-C levels in patients in the MARINE and ANCHOR studies, including significant reductions in RLP-C in hypertriglyceridemic patients with TG &gt;=200 mg/dL or &gt;=500 mg/dL receiving statin therapy.
Decline in hepatitis E virus antibody prevalence in southeastern Germany, 1996-2011
Authors: Jürgen J. Wenzel, Mathias Sichler, Mathias Schemmerer, Gundula Behrens, Michael F. Leitzmann, Wolfgang Jilg
Journal: Hepatology (2014)

In the past decade, an increasing frequency of acute hepatitis E was noted in Germany and other European countries. Moreover, a high prevalence (17%) of hepatitis E virus (HEV) immunoglobulin G antibodies (anti-HEV) was recently found in the adult German population. Although this suggests an emerging pathogen, reports from other countries gave hints to a completely new aspect: a possible decrease in anti-HEV prevalence during the last decades. To investigate the time trends of hepatitis E in southeastern Germany, we performed anti-HEV testing in sera taken from adults in 1996 and 2011. Surplus serum specimens stored during routine operations of our diagnostic laboratory were used. The sample comprised two sets of 1,092 sera taken in 1996 and 2011, each with 182 specimens in six age groups from 20-79 years. Testing was performed using an HEV IgG enzyme immunoassay (EIA, Axiom Diagnostics), and the recomLine HEV IgG immunoblot (Mikrogen). A significant difference in anti-HEV prevalence was observed between the two groups: 50.7% of individuals tested positive in the 1996 group as compared to 34.3% in 2011 (EIA, P < 0.001). Results by immunoblot analysis were 20.5% (1996) versus 14.5% (2011), P < 0.001. Differences were found in all age groups and were more pronounced for the 20-39-year age group. The prevalence of anti-HEV has decreased significantly in the past decades in southeastern Germany. The phenomenon of HEV being an emerging pathogen is thus most probably due to an increasing awareness of the disease.
Drug-induced sleep endoscopy predictors for oral appliance treatment outcome
Authors: Anneclaire Vroegop, Marc Braem, Paul Van de Heyning, Olivier Vanderveken
Journal: European Respiratory Journal (2013)

Introduction: During a drug-induced sleep endoscopy (DISE), a flexible nasopharyngoscope is used to visualize the upper airway (UA) during artificial sleep. The aim of this study was to assess the associations between UA patterns and treatment outcome of mandibular advancement device (MAD) therapy for obstructive sleep apnea (OSA).  Methods: Patients underwent baseline polysomnography (PSG), DISE and PSG with MAD after an acclimatization period. The associations between the findings during DISE and treatment outcome in terms of apnea hypopnea index (AHI) reduction were evaluated, by means of a multiple logistic regression. Treatment response was defined as a >50% decrease in AHI.  Results: 247 patients underwent DISE before MAD treatment [age 47±9.1y; AHI 20.4±14.8/h; body mass index (BMI) 27.0±3.9 kg/m²]. The results of this study demonstrated a statistically significant association between presence of a palatal collapse during DISE and treatment response with MAD, after correction for BMI, age and gender (p  Conclusion: The results of this study indicate that the presence of a palatal collapse during DISE is predictor of treatment response with MAD in OSAS. These findings may allow for improved patient selection for this specific therapy.
Urinary 11β‐<scp>PGF</scp>2α and N‐methyl histamine correlate with bone marrow biopsy findings in mast cell disorders
Authors: R. Divekar, J. Butterfield
Journal: Allergy (2015)

The utility of measuring histamine and prostaglandin metabolites in the urine of patients with mastocytosis has not been critically examined in a large series of patients. This study examined the relationship between the extent of increase in urinary excretion of 11β-prostaglandinF2α and N-methyl histamine, with serum tryptase, whole blood serotonin, and bone marrow findings including morphology, percentage involvement, and abnormal mast cell phenotype.This was a retrospective analysis of 90 patients who were continuously enrolled in the study for a period of 6 years (2008-2014). We recorded serum tryptase, whole blood serotonin, levels of urinary mast cell metabolites 11β-prostaglandinF2α and N-methyl histamine (NMH), and bone marrow findings.Urinary mast cell metabolites 11β-prostaglandinF2α and N-methyl histamine correlated with levels of serum tryptase, mast cell burden in the bone marrow, the presence of mast cell aggregates, and atypical mast cells on bone marrow biopsy. Whole blood serotonin did not have a significant correlation with the serum tryptase or mast cell burden in the bone marrow. Urinary NMH was significantly different between c-kit D816V-positive and c-kit D816V-negative patients, while 11β-prostaglandinF2α was not. Urinary 11β-prostaglandinF2α 24-h excretion >3500 ng and NMH levels >400 μg/gm Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, the presence of aggregates, and c-kit mutation.Easily obtained and quantified urinary metabolites of histamine (greater than twice the upper limit of normal) and prostaglandin D2 (>3.4 times the upper limit of normal) correlate well with bone marrow findings of mastocytosis.
Virus-Like Particles in Cow's Milk From a Herd With a High Incidence of Lymphosarcoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Ray M. Dutcher, Edward P. Larkin, Robert R. Marshak
Journal: JNCI Journal of the National Cancer Institute (1964)

Particles with diameters of approximately 60 and 110 mμ were detected in concentrated milk from cows in a herd (BF) with a high incidence of lymphosarcoma. The milk samples were negatively stained with phosphotungstic acid and examined with the electron microscope. Similar particles were not observed in 8 milk samples from cows in a lymphosarcoma-free herd (Cl). However, pool tank samples from 2 lymphosarcoma-free herds (Cl and Bl) contained particles. Thin sections of milk pellets from individual cattle as well as samples from a herd (BF) with a high incidence of lymphosarcoma contained particles with double membranes, dense nucleoids, and other miscellaneous particles. Sections of sample milk pellets from the lymphosarcoma-free herd (Cl) did not contain particles with double membranes and dense nucleoids. When processed in a potassium citrate density gradient, milk concentrates from the BF herd contained characteristic particles in a distinct band with a buoyant density of 1.16 g per cm3. When pelleted and resuspended, this band contained tailed particles.
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
Authors: Anna Hultberg, Virginia Morello, Leander Huyghe, Natalie De Jonge, Christophe Blanchetot, Valérie Hanssens, Gitte De Boeck, Karen Silence, Els Festjens, Raimond Heukers, Benjamin Roux, Fabienne Lamballe, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Flavio Maina, Peter Brouckaert, Michael Saunders, Alain Thibault, Torsten Dreier, Hans de Haard, Paolo Michieli
Journal: Cancer Research (2015)

Hepatocyte growth factor (HGF) and its receptor MET represent validated targets for cancer therapy. However, HGF/MET inhibitors being explored as cancer therapeutics exhibit cytostatic activity rather than cytotoxic activity, which would be more desired. In this study, we engineered an antagonistic anti-MET antibody that, in addition to blocking HGF/MET signaling, also kills MET-overexpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC). As a control reagent, we engineered the same antibody in an ADCC-inactive form that is similarly capable of blocking HGF/MET activity, but in the absence of any effector function. In comparing these two antibodies in multiple mouse models of cancer, including HGF-dependent and -independent tumor xenografts, we determined that the ADCC-enhanced antibody was more efficacious than the ADCC-inactive antibody. In orthotopic mammary carcinoma models, ADCC enhancement was crucial to deplete circulating tumor cells and to suppress metastases. Prompted by these results, we optimized the ADCC-enhanced molecule for clinical development, generating an antibody (ARGX-111) with improved pharmacologic properties. ARGX-111 competed with HGF for MET binding, inhibiting ligand-dependent MET activity, downregulated cell surface expression of MET, curbing HGF-independent MET activity, and engaged natural killer cells to kill MET-expressing cancer cells, displaying MET-specific cytotoxic activity. ADCC assays confirmed the cytotoxic effects of ARGX-111 in multiple human cancer cell lines and patient-derived primary tumor specimens, including MET-expressing cancer stem-like cells. Together, our results show how ADCC provides a therapeutic advantage over conventional HGF/MET signaling blockade and generates proof-of-concept for ARGX-111 clinical testing in MET-positive oncologic malignancies.
Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.
Authors: J M Bennett, A B Troxel, R Gelman, G Falkson, M D Coccia-Portugal, R Dreicer, D C Tormey, D Rushing
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.4.874 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8151329 Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer. J M BennettxJ M BennettSearch for articles by this author , A B TroxelxA B TroxelSearch for articles by this author , R GelmanxR GelmanSearch for articles by this author , G FalksonxG FalksonSearch for articles by this author , M D Coccia-PortugalxM D Coccia-PortugalSearch for articles by this author , R DreicerxR DreicerSearch for articles by this author , D C TormeyxD C TormeySearch for articles by this author , D RushingxD RushingSearch for articles by this author Show More https://doi.org/10.1200/JCO.1994.12.4.874 PDF "Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.." Journal of Clinical Oncology, 12(4), pp. 874–875© 1994 by American Society of Clinical Oncology